menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    [{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"BW-02","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Argo Biopharma \/ Novartis Pharmaceuticals Corporation"}]

    Find Clinical Drug Pipeline Developments & Deals by Argo Biopharma

    Menu

    Argo Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Argo Biopharma

    China arrow
    ELCC
    Not Confirmed

    Argo Biopharma

    China arrow
    ELCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : BW-02

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase I

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : $4,165.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Shanghai Argo Announces RNAi Licenses and Collaborations with Novartis

    Details : Argo has granted Novartis global licenses to develop and commercialize a Phase 1 program, allowing Novartis to select targets and drive discovery and optimization of lead candidates.

    Product Name : BW-02

    Product Type : Oligonucleotide

    Upfront Cash : $185.0 million

    January 07, 2024

    Lead Product(s) : BW-02

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase I

    Sponsor : Novartis Pharmaceuticals Corporation

    Deal Size : $4,165.0 million

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth